tbuckley/cabot-search huggingface dataset:
Abstract P4-01-12: Compliance with Recommended Follow-Up after MRI-guided Core Needle Biopsy of Suspicious Breast Lesions: A Retrospective Study
Authors: MO Thompson, JA Lipson, BL Daniel, CL Harrigal, PJ Mullarkey, DM Ikeda
Journal: Cancer Research (2012)

Abstract Purpose: The purpose of this study was to assess patient compliance with recommended follow-up after MRI-guided core needle biopsy and investigate the reasons why patients did not comply with their recommended MRI imaging follow-up. Materials and Methods: A HIPAA compliant retrospective review was performed of 576 MRI-guided core needle biopsies between 2007–2010 with IRB approval and waiver of informed consent. Of 576 biopsies, 73.3% (422/576) were compliant and 26.7% (154/576) were noncompliant with follow-up recommendations and composed this study. Imaging and surgical planning was determined by comparing imaging findings, clinical findings, and biopsy histology. Results: Out of 135 lesions in patients noncompliant with follow-up imaging, 50.4% (68/135) were referred for biopsy by non-affiliated physicians, 41.5% (56/135) received a screening MRI, and 40.3% (56/135) were a focus or foci. Referring physicians provided information regarding the follow-up status of 88/154 (57%) lesions in noncompliant patients, of which 44/88 (50%) were followed by mammogram instead of MRI. Among compliant patients, 7/178 (3.9%) lesions seen on follow-up MRI were found to be high risk or malignant. Conclusion: Compliance with follow-up MRI recommendation after core needle biopsy is low. Three characteristics were found to be associated with noncompliance with follow-up imaging: referral from non-affiliated physician, screening MRI, and a focus lesion. Moreover, patients who do not comply with recommended MRI follow-up are more likely to have follow-up mammography. Follow-up imaging among compliant patients found high-risk lesions and malignancy. Facilities performing MRI-guided core biopsies should therefore be aware of a high risk of noncompliance with follow-up. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-01-12.
Abstract 2999: Role of heterogeneous nuclear ribonucleoprotein A/Bs in telomere maintenance
Authors: Tzu-Chien V. Wang, Pei-Rong Huang, Yuan-Ming Yeh, Shu-Chen Hung
Journal: Cancer Research (2011)

Abstract Heterogeneous nuclear ribonucleoproteins (hnRNPs) constitute a large family of proteins that associate with nascent pre-mRNAs, packaging them into hnRNP particles. In addition to their action as RNA-binding proteins, several members of the hnRNP family are thought to play roles in telomere maintenance because they are known to bind to telomeric DNA and to TERRA RNA, which is now identified as an integral component of telomeric heterochromatin. Using affinity purification and proteomic approach, we have previously shown that the members of hnRNP A/B family are the most abundant proteins in the nuclear extracts that bound specifically to G-strand telomeric DNA. To address if members of hnRNP A/B family are essential components of a functional telomere (i.e., does hnRNP A/Bs play a structural role) and to determine the functional overlap among members of hnRNP A/Bs in telomere length regulation, we initiated to investigate the biological effects of single, double, or triple knock-down of hnRNP A1, A2/B1 or A3. Preliminary results obtained from transient depletion of single hnRNP A1, A2 or A3 by RNA interference (RNAi) indicated that depletion of hnRNP A2 or A3 significantly reduced cell growth and colony formation. The percentage of cells in the sub-G1 phase was increased following the knockdown of hnRNP A2 or A3. In addition, the expression of S-phase kinase-associated protein-2 (skp2) was decreased in the transient knock-down cells. Surprisingly, however, studies of stable clones derived from single knock-down experiments indicated that knock-down of hnRNP A2, but not A1 or A3, produced a profound effect on cellular growth. This effect does not appear to result from reduced viability and/or apoptosis. We noted that an increased expression of hnRNP A1 was always observed in the stable clones depleted of hnRNP A3. Similarly, increased expression of A3 was observed in the cells depleted of hnRNP A1, suggesting that hnRNP A1 and A3 may have functional redundancy in vivo. Works are in progress to determine whether the anti-proliferation effects of depleting hnRNP A/B may result from telomere dysfunction, and to investigate the functional overlap between hnRNP A/Bs using double knock-down approach. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2999. doi:10.1158/1538-7445.AM2011-2999
FRI0476-HPR Accuracy of a new three dimension postural analysis system based on low cost infrared sensors and emmiters:
Authors: T.N. Burke, F.R. França, A.D. Neto, L.V. Ramos, R.R. Caffaro, A.P. Marques
Journal: Annals of the Rheumatic Diseases (2013)

Background Postural assessment is regarded as the initial physical examination basic procedure to be conducted on patients [1]. However, most existing systems for postural assessment do not use the methodology of real-time scanning of anatomical markers, which could increase the error during the process and analyze posture only in two dimensions. Other systems such as computed tomography, infrared cameras, electrogioniometers or the use of ultrasound, assess posture in three dimensions but are not easily accessible [2,3]. Objectives Develop and verify the accuracy of a low cost 3D postural analysis system based on the automatic scanning of anatomical points by infrared sensors. Methods The System was developed using the Nintendo Wii videogame controller as a infrared sensor and infrared LEDs as body markers. The sensor tracks each spatial marker coordinates and send them to the computer by bluetooth connection. To calculate distances, the System uses the Pythagorean Theorem d2=(xb-xa)2 + (yb-ya)2 and to calculate angles, the Law of cosines a2 =b2+c2-2bc.cosθ. To the accuracy evaluation, the markers were positioned at a distance of 2.5 meters of the Wiimote, at the same plane, and the system was calibrated with two markers, positioned at 50 cm between them (distance measured by a digital precision caliper). After the calibration, the LEDs distance was modified to 56 cm and the system tracked the new markers position. Another marker was added, randomly, generating an unknown triangle. The three inner angles were measured and the values summed. The value found was compared with the expected sum (180o), according to the interior angle sum theorem. The differences between the known values and those found were considered as system error. Results The system error for distances was 4 mm and for angles was zero degrees. View this table: Conclusions The system showed good accuracy in measuring angles and distances, with erros of 0% and 0,7%, respectively and can be useful for clinical use and for scientific research. The next step is to develop an algorithm to calculate the sagittal and coronal curvatures of the spine in real time. The system can be useful for clinicians because of the low cost and the good applicability. 1. Cocchiarella L, Anderson GBJ. Guides to the evaluation of permanent impairment. AMA Press; 2001.p.375–422. 2. Christensen HW, Nilsson N. The ability to reproduce the neutral zero position of the head. J Manipulative Physiol Ther 1999, 22: 26-28. 3. Strimpakos N, Sakellari V, Gioftsos G, Papathanasiou M, Brountzos E, Kelekis D, Kapreli E, Oldham J. Cervical spine ROM measurements: optimizing the testing protocol by using a 3D ultrasound-based motion analysis system. Cephalgia 2005, 25: 1133-45. Disclosure of Interest None Declared
COMPARISON OF 5-YEAR CLINICAL OUTCOMES IN ASYMPTOMATIC VERSUS SYMPTOMATIC PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING AORTIC VALVE REPLACEMENT
Authors: Shinichi Shirai, Tomohiko Taniguchi, Takeshi Morimoto, Kenji Ando, Kengo Korai, Kenji Minakata, Michiya Hanyu, Tadaaki Koyama, Tatsuhiko Komiya, Ryuzo Sakata, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2016)
P13.06 * IS SAFE TO COMBINE HYPOFRACTIONATION AND LOW DOSE FRACTIONATED RADIATION THERAPY WITH TEMOZOLOMIDE IN NAIVE UNRESECTABLE GLIOBLASTOMA? - RESULTS OF A PILOT STUDY
Authors: S. Chiesa, M. Ferro, B. Diletto, A. Alitto, M. Vernaleone, D. Marchesano, C. Colosimo, G. Maira, C. Anile, M. Balducci
Journal: Neuro-Oncology (2014)

OBJECTIVE: To explore safety and efficacy of hypofractionated radiotherapy (HyRT) followed by low dose radiation therapy (LDRT) in combination with Temozolomide (TMZ) in adults with newly diagnosed Glioblastoma Multiforme. MATERIAL AND METHODS: Patients (ECOG ≤2, age ≥18 years) with a previous biopsy or a gross residual tumor after surgery were enrolled in this study. Treatment started with HyRT (30 Gy in ten fraction) combined with TMZ (75 mg/m2 for all time of RT) followed by adjuvant TMZ. From the second to third cycle of adjuvant TMZ, LDRT (0.40 Gy twice daily, at least 4 hours apart over 5 consecutive days, every 28 days) was planned. Another 2 cycles were scheduled if neither progression disease nor clinical decrease was observed. Conformal irradiation included the tumor with surgical cavity, plus a 30-mm margin. The primary endpoints were safety, tolerability and toxicity according to Common Terminology Criteria for Adverse Events version 4.0. Response according to RANO Guidelines, Overall Survival, Progression-free survival (PFS) were the secondary endpoints. RESULTS: From June 2008 to January 2012, 20 patients with a median age of 64.5 years were enrolled. All patients received the prescribed dose of 30 Gy. 17 out of twenty received 2 cycles of LDRT and the median total dose was 12 Gy. All toxicities were reversible and only 5 patients presented hematologic G1-2 toxicity. At the end of the fourth cycle, 4 out of 20 patients had partial response, 6 experienced stable disease and 10 patients had progressive disease Median OS and PFS from diagnosis were 14 and 11 months, respectively. Patients who received ≤2 cycles presented a median OS and PFS of 5 and 4 months respectively; when four cycles were administered the median OS was 26 months and PFS was 14 months. CONCLUSIONS: Hypofractionated regimen followed by LD-FRT combined with TMZ is safe and tolerated well. The number of LDFRT's cycles seems to increase the survival in this setting of patients. A new study is ongoing.
Upper-Limb Robotic Exoskeletons for Neurorehabilitation: A Review on Control Strategies
Authors: Tommaso Proietti, Vincent Crocher, Agnes Roby-Brami, Nathanael Jarrasse
Journal: IEEE Reviews in Biomedical Engineering (2016)

Since the late 1990s, there has been a burst of research on robotic devices for poststroke rehabilitation. Robot-mediated therapy produced improvements on recovery of motor capacity; however, so far, the use of robots has not shown qualitative benefit over classical therapist-led training sessions, performed on the same quantity of movements. Multidegree-of-freedom robots, like the modern upper-limb exoskeletons, enable a distributed interaction on the whole assisted limb and can exploit a large amount of sensory feedback data, potentially providing new capabilities within standard rehabilitation sessions. Surprisingly, most publications in the field of exoskeletons focused only on mechatronic design of the devices, while little details were given to the control aspects. On the contrary, we believe a paramount aspect for robots potentiality lies on the control side. Therefore, the aim of this review is to provide a taxonomy of currently available control strategies for exoskeletons for neurorehabilitation, in order to formulate appropriate questions toward the development of innovative and improved control strategies.
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Authors: Caro Schaake-Koning, Walter van den Bogaert, Otilia Dalesio, Jan Festen, Jaap Hoogenhout, Paul van Houtte, Anne Kirkpatrick, Mia Koolen, Ben Maat, Arie Nijs, Alain Renaud, Patrick Rodrigus, Lon Schuster-Uitterhoeve, Jean-Paul Sculier, Nico van Zandwijk, Harry Bartelink
Journal: New England Journal of Medicine (1992)

Cisplatin (cis-diamminedichloroplatinum) has been reported to enhance the cell-killing effect of radiation, an effect whose intensity varies with the schedule of administration. We randomly assigned 331 patients with nonmetastatic inoperable non-small-cell lung cancer to one of three treatments: radiotherapy for two weeks (3 Gy given 10 times, in five fractions a week), followed by a three-week rest period and then radiotherapy for two more weeks (2.5 Gy given 10 times, five fractions a week); radiotherapy on the same schedule, combined with 30 mg of cisplatin per square meter of body-surface area, given on the first day of each treatment week; or radiotherapy on the same schedule, combined with 6 mg of cisplatin per square meter, given daily before radiotherapy.Survival was significantly improved in the radiotherapy-daily-cisplatin group as compared with the radiotherapy group (P = 0.009): survival in the radiotherapy-daily-cisplatin group was 54 percent at one year, 26 percent at two years, and 16 percent at three years, as compared with 46 percent, 13 percent, and 2 percent, respectively, in the radiotherapy group. Survival in the radiotherapy-weekly-cisplatin group was intermediate (44 percent, 19 percent, and 13 percent) and not significantly different from survival in either of the other two groups. The survival benefit of daily combined treatment was due to improved control of local disease (P = 0.003). Survival without local recurrence was 59 percent at one year and 31 percent at two years in the radiotherapy-daily-cisplatin group; 42 percent and 30 percent, respectively, in the radiotherapy-weekly-cisplatin group; and 41 percent and 19 percent, respectively, in the radiotherapy group. Cisplatin induced nausea and vomiting in 86 percent of the patients given it weekly and in 78 percent of those given it daily; these effects were severe in 26 percent and 28 percent, respectively.Cisplatin, given daily in combination with the radiotherapy described here to patients with nonmetastatic but inoperable non-small-cell lung cancer, improved rates of survival and control of local disease at the price of substantial side effects.
Abstract 428: Positive correlation of beta1 integrin expression and prognosis in clinically localized prostate cancer
Authors: Jose Pontes Jr, Leopoldo Alves Ribeiro-Filho, Sabrina T. dos Reis, Luciana Timoszczuk, Felipe S. Bernardes, Alberto A. Antunes, Nayara I. Viana, Carlo C. Passerotti, Luiz CN Oliveira, Ellen Hagopian, Marcos F. Dall'Oglio, Katia RM Leite, Miguel Srougi
Journal: Cancer Research (2011)

Abstract Introduction and objective: Integrins are transmembrane glycoprotein receptors that regulate cell-matrix interactions, functioning as sensors of the environment. They also act as cell adhesion molecules, being responsible for the maintenance of the epithelial phenotype. Some studies have reported correlation between alterations of integrins expression and carcinogenesis, specially β1 integrin, but their role in prostate cancer is unclear. Our aim is to study the expression of β1 integrin and evaluate its association with recurrence of prostate cancer after surgical treatment Methods: For this case-control study, we selected 111 patients with localized tumor submitted to radical prostatectomy by the same surgeon. 60 of these patients have not presented recurrence after a median follow-up of 123 months. Recurrence was defined as a PSA level above 0.4ng/ml. Integrin expression was evaluated by immunohistochemistry in a Tissue Microarray containing two samples from each tumor. We employed a semiquantitative analysis and considered a case as positive when the expression was strong and diffusely present. We correlated expression with recurrence employing the χ2 test and p&amp;lt;0.05 was considered significant. Results: Positive expression of β1 integrin was found in 79 out of 100 evaluated cases, ten cases were lost in the tissue microarray. Correlating expression with recurrence we found in the univariate analysis that negative expression of β1 integrin was statistically associated with recurrence (p=0,042) and time to recurrence after radical prostatectomy, when expression of β1 is negative, the odds of recurrence was two times higher than that observed in positive cases (p=0.026 – IC 95% [1.09; 3.83]. In multivariate analysis, including PSA and Gleason, β1 integrin remained independently associated with recurrence p=0.01. Conclusions: In the present study we have shown that a down regulation of β1integrin expression was significantly correlated with recurrence after radical prostatectomy for localized prostate cancer, making this integrin a potential candidate as a marker of prognosis. Larger series will be evaluated in order to confirm our initial findings Figure Kaplan Meier curve for recurrence-free survival according to β1expression in 111primaryPCa submitted to RP Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 428. doi:10.1158/1538-7445.AM2011-428
CLINICAL SIGNIFICANCE OF CHANGES IN THE CORRECTED QT INTERVAL IN STRESS-INDUCED CARDIOMYOPATHY
Authors: Jung-Hee Lee, Jae-Sun Uhm, Tae-Hoon Kim, Hancheol Lee, Junbeom Park, Jin-Kyu Park, Boyoung Joung, Hui-Nam Pak, Young-Guk Ko, Geu-Ru Hong, Moon-Hyoung Lee
Journal: Journal of the American College of Cardiology (2015)
FRI0396 Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (scleroderma lung study [SLS] II): rationale, design, methods, baseline characteristics and patient disposition
Authors: D. Khanna, M. Roth, D. Furst, P. Clements, J. Goldin, E. Arriola, J. Kotlerman, C.-H. Tseng, G. Kim, R. Elashoff, D. Tashkin
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Cyclophosphamide (CYC), is the only therapy that has been shown thus far to be efficacious in scleroderma-related interstitial lung disease (SSc-ILD). However, the utility of CYC is constrained by its toxicity, which limits treatment to only ≤1 year. Findings from several uncontrolled studies in small numbers of patients with SSc-ILD (n≤17) suggest that mycophenolate mofetil (MMF) is a safe and effective treatment for SSc-ILD. <h3>Methods</h3> SLS II is a double-blind, double-dummy, parallel-group randomized controlled trial (DB DD PG RCT) comparing the efficacy and safety of MMF (titrated to 3 g/d over 2 years) versus oral CYC (titrated to 2 mg/kg/d for 1 year followed by placebo for another year) in patients with active SSc-ILD (target enrollment 150 patients). Key eligibility criteria included adults, <b>≤</b> 7 yrs, any ground glass opacity (GGO) as an indication of "active" disease, and FVC% between 40-80% predicted. <i>Procedures</i>: Spirometry, lung volumes, DLCO, SGRQ, SF-12, modified Rodnan skin score (mRSS), and cough questionnaire at screening and/or baseline and every 3 months for 2 yrs; BDI (baseline); TDI every 3 months for 2 yrs; HRCT (screening and 2 years ;central reading center); toxicity monitoring. <i>Statistical analysis</i>: Primary endpoints: FVC % pred at 2 yrs, adjusted for baseline FVC % pred and "fibrosis" score on screening HRCT and toxicity outcomes over 2 yrs. <h3>Results</h3> Baseline results are presented in Table 1. Premature discontinuation of study drug (38/130) – due to drug toxicity (13/38); failure to return for 24-month visits (12/26 due); SAEs (38) – 5 felt to be study-related; 1/130 treatment failure (defined by 15% pred decrease in FVC sustained for ≥1 mo). <h3>Conclusions</h3> A DB DD RCT of oral CYC for 1 yr versus MMF for 2 yrs in patients with progressive SSc-ILD is feasible with a low rate (10%) of discontinuations due to drug toxicity overall. Extent of ILD on HRCT is significantly, albeit modestly, correlated with physiologic impairment, supporting the use of change in HRCT scores from baseline as a key endpoint. <b>Disclosure of Interest</b>: None Declared
TCT-476 Antithrombotic Therapy In Patients With Chronic Kidney Disease And Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From The AVIATOR Registry
Authors: Georgios Christodoulidis, Marco G. Mennuni, Samantha Sartori, Usman Baber, George Dangas, Ioannis Mastoris, Samin Sharma, Annapoorna Kini, Corrado Tamburino, Alaide Chieffo, Antonio Colombo, Patrizia Presbitero, Roxana Mehran
Journal: Journal of the American College of Cardiology (2014)
SP0107 Ehealth Literacy among Patients with Rheumatic Diseases; Present and Future Perspectives
Authors: R. Van Der Vaart
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The Internet offers diverse opportunities for disease management, through information websites (Health 1.0) and interactive applications such as peer support forums, e-consults and insight into electronic medical records (Health 2.0). However, it requires various skills to use the Internet in a meaningful way, so-called "eHealth literacy". Our objective was to study the eHealth literacy of patients with rheumatic diseases and the types of problems they encounter when using the Internet in relation to their disease. <h3>Methods</h3> In two studies, eHealth literacy was observed. In study 1, 15 patients (aged 39-74) performed six information-retrieval tasks on the Internet (Health 1.0). In study 2, 16 patients (aged 24-72) performed three Health 2.0 tasks on a hospital-based online web portal and two Health 2.0 tasks on interactive websites. Participants were asked to think aloud while performing the assignments, and screen activities were recorded. Types and frequency of problems were categorized by two independent researchers. <h3>Results</h3> Nearly all participants experienced difficulties, and a substantial number of participants was not able to complete all assignments. Encountered problems could be divided into six sequential categories: (1) operating the computer and Internet browser, (2) navigating and orientating on the Web, (3) utilizing search strategies, (4) evaluating relevance and reliability, (5) adding content to the Web, and (6) protecting and respecting privacy. Most severe difficulties occurred in levels 3 and 4; in formulating a search query, evaluating the source of the information, and in scanning a website for relevant information. <h3>Conclusions</h3> Many patients have insufficient skills to properly use Web 1.0 and Web 2.0. Our findings may contribute to the consensus between online applications and patients9 eHL. For example, via the development of a toolbox for health professionals or a course for patients with low eHealth literacy. Furthermore, these results provide input for the development of an instrument to measure eHealth literacy skills in a efficient and valid manner. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6251
None of predicted negative effects of plain cigarette packs has emerged, says study
Authors: A. O'Dowd
Journal: BMJ (2014)

Introducing plain packaging of tobacco products has not led to any of the negative consequences that the industry predicted, concludes a study published in BMJ Open .1

Australian researchers found that the policy had not damaged small retailers’ business, nor had it flooded the market with cheap cigarettes or boosted the trade in illicit tobacco. Australia was the first country to introduce standardised packaging of tobacco products in December 2012. Similar legislation is currently being considered in the United Kingdom, New Zealand, and Ireland. …